Biomarkers /
CYSLTR2
Overview
CYSLTR2 is altered in 1.58% of all cancers with prostate adenocarcinoma, lung adenocarcinoma, colon adenocarcinoma, uterine corpus leiomyosarcoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in CYSLTR2 are CYSLTR2 Loss (0.94%), CYSLTR2 Mutation (0.53%), CYSLTR2 Amplification (0.08%), CYSLTR2 E343K (0.02%), and CYSLTR2 R136H (0.02%) [3].
Clinical Trials
Significance of CYSLTR2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.